首页> 外文期刊>Human Reproduction >Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling.
【24h】

Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling.

机译:囊性纤维化跨膜电导调节剂(CFTR)基因重排的检测可丰富先天性双侧输精管缺失的突变谱,并影响遗传咨询。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Mutations in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene have been widely detected in infertile men with congenital bilateral absence of the vas deferens (CBAVD). Despite extensive analysis of the CFTR gene using varied screening methods, a number of cases remain unsolved and could be attributable to the presence of large gene rearrangements, as recently shown for CF patients. METHODS: We carried out a complete CFTR gene study in a group of 222 CBAVD patients with strict diagnosis criteria and without renal anomaly, and searched for rearrangements using a semi-quantitative assay in a subgroup of 61 patients. RESULTS: The overall mutation detection rate was 87.8%, and 82% of patients carried two mutations. Ten out of the 99 different mutations accounted for 74.6% of identified alleles. Four large rearrangements were found in patients who already carried a mild mutation: two known partial deletions (exons 17a to 18 and 22 to 23), a complete deletion and a new partial duplication (exons 11 to 13). The rearrangements accounted for 7% of the previously unknown alleles and 1% of all identified alleles. CONCLUSIONS: Screening for rearrangements should be part of comprehensive CFTR gene studies in CBAVD patients and may have impacts on genetic counselling for the patients and their families.
机译:背景:在先天性双侧输精管缺失(CBAVD)的不育男性中,囊性纤维化(CF)跨膜电导调节剂(CFTR)基因的突变已得到广泛检测。尽管使用不同的筛选方法对CFTR基因进行了广泛分析,但仍有许多病例尚未解决,这可能归因于存在较大的基因重排,如最近针对CF患者的研究所示。方法:我们对一组222例诊断标准严格且无肾异常的CBAVD患者进行了完整的CFTR基因研究,并在61例亚组中使用半定量分析搜索了重排。结果:总的突变检测率为87.8%,其中82%的患者进行了两次突变。在99个不同的突变中,有10个占已鉴定等位基因的74.6%。在已经进行了轻度突变的患者中发现了四个大的重排:两个已知的部分缺失(外显子17a至18和22至23),一个完全缺失和一个新的部分重复(外显子11至13)。重排占先前未知等位基因的7%和所有已鉴定等位基因的1%。结论:筛查重排应该是CBAVD患者全面CFTR基因研究的一部分,并且可能对患者及其家属的遗传咨询产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号